Form 8-K - Current report:
SEC Accession No. 0001628280-23-002037
Filing Date
2023-02-02
Accepted
2023-02-02 16:02:04
Documents
16
Period of Report
2023-02-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20230202.htm   iXBRL 8-K 44892
2 EX-10.1 a101ex020223.htm EX-10.1 87401
3 EX-99.1 a991ex020223.htm EX-99.1 18399
7 crdf-20230202_g1.jpg GRAPHIC 2732
8 image_0.jpg GRAPHIC 17928
  Complete submission text file 0001628280-23-002037.txt   339589

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20230202.xsd EX-101.SCH 1923
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20230202_lab.xml EX-101.LAB 22875
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20230202_pre.xml EX-101.PRE 11999
10 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20230202_htm.xml XML 10063
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 23580787
SIC: 2836 Biological Products, (No Diagnostic Substances)